WA
CSTL icon

Wasatch Advisors’s Castle Biosciences CSTL Stock Holding History

Wasatch Advisors’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.66M Sell
279,349
-175,687
-39% -$3.91M 0.04% 163
2026
Q1 		$11.2M Sell
455,036
-82,205
-15% -$2.69M 0.07% 124
2025
Q4 		$20.9M Sell
537,241
-131,879
-20% -$4.25M 0.12% 124
2025
Q3 		$15.2M Sell
669,120
-380,653
-36% -$7.73M 0.08% 138
2025
Q2 		$21.4M Buy
1,049,773
+51,318
+5% +$950K 0.11% 129
2025
Q1 		$20M Sell
998,455
-797,633
-44% -$19.7M 0.11% 128
2024
Q4 		$47.9M Sell
1,796,088
-30,004
-2% -$914K 0.24% 99
2024
Q3 		$52.1M Sell
1,826,092
-501,844
-22% -$12.8M 0.26% 94
2024
Q2 		$50.7M Sell
2,327,936
-223,152
-9% -$4.97M 0.27% 86
2024
Q1 		$56.5M Sell
2,551,088
-39,863
-2% -$867K 0.3% 84
2023
Q4 		$55.9M Sell
2,590,951
-189,793
-7% -$3.34M 0.31% 79
2023
Q3 		$47M Sell
2,780,744
-306,257
-10% -$5.36M 0.3% 80
2023
Q2 		$42.4M Buy
3,087,001
+107,088
+4% +$2.17M 0.26% 85
2023
Q1 		$67.7M Sell
2,979,913
-242,649
-8% -$5.93M 0.42% 67
2022
Q4 		$75.9M Sell
3,222,562
-122,185
-4% -$2.83M 0.51% 59
2022
Q3 		$87.2M Sell
3,344,747
-360,771
-10% -$10.1M 0.61% 52
2022
Q2 		$81.3M Buy
3,705,518
+261,671
+8% +$6.08M 0.51% 66
2022
Q1 		$154M Buy
3,443,847
+327,359
+11% +$13.5M 0.76% 46
2021
Q4 		$134M Buy
3,116,488
+622,786
+25% +$32.5M 0.55% 63
2021
Q3 		$166M Sell
2,493,702
-11,196
-0.4% -$788K 0.67% 51
2021
Q2 		$184M Buy
2,504,898
+151,419
+6% +$10M 0.75% 45
2021
Q1 		$161M Buy
2,353,479
+288,648
+14% +$21.7M 0.72% 50
2020
Q4 		$139M Buy
2,064,831
+686,774
+50% +$37.2M 0.68% 53
2020
Q3 		$70.9M Buy
1,378,057
+286,275
+26% +$12.7M 0.45% 73
2020
Q2 		$41.1M Buy
1,091,782
+441,637
+68% +$15.1M 0.3% 94
2020
Q1 		$19.4M Buy
650,145
+273,778
+73% +$8.26M 0.2% 98
2019
Q4 		$12.9M Buy
376,367
+100,856
+37% +$2.47M 0.11% 131
2019
Q3 		$4.98M Buy
+275,511
New +$6.11M 0.05% 184

Other funds holding CSTL

YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
FBT
First Bank & Trust Brookings, South Dakota $680M AUM 25.36% 1-Year Est. Return
CMF
Counterpoint Mutual Funds San Diego, California $1.01B AUM 37.65% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return
CWP
Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return
FHC
First Horizon Corporation Memphis, Tennessee $2.6B AUM 23.72% 1-Year Est. Return
HFS
Hughes Financial Services Herndon, Virginia $755M AUM 20.43% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
BL
BFSG LLC Irvine, California $1.13B AUM 29.95% 1-Year Est. Return

Wasatch Advisors's CSTL Position: Q2 2026 in Review

Wasatch Advisors reduced its Castle Biosciences (CSTL) stake by 39% in Q2 2026, selling an estimated $3.91M and leaving 279,349 shares worth $6.66M. The position accounts for 0.04% of the portfolio, ranked #163.

Wasatch Advisors first reported a position in CSTL in Q3 2019 and has held it in 28 quarters since. The position peaked at $184M in Q2 2021. 16 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Wasatch Advisors held 279,349 shares of Castle Biosciences worth $6.66M as of Q2 2026.
  • Wasatch Advisors sold 175,687 Castle Biosciences shares in Q2 2026, an estimated $3.91M.
  • Castle Biosciences made up 0.04% of Wasatch Advisors's portfolio in Q2 2026, its #163 holding.
  • Wasatch Advisors first reported a position in Castle Biosciences in Q3 2019 and has held it in 28 quarters since.
  • Wasatch Advisors's Castle Biosciences position peaked at $184M in Q2 2021.
  • 16 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Wasatch Advisors's 13F filing for Q2 2026, filed 10 Jul 2026.